Haemonetics (NYSE:HAE) Earns Buy Rating from BTIG Research

Haemonetics (NYSE:HAE)‘s stock had its “buy” rating restated by equities research analysts at BTIG Research in a research note issued to investors on Friday,Benzinga reports. They currently have a $88.00 target price on the medical instruments supplier’s stock. BTIG Research’s target price would suggest a potential upside of 48.27% from the company’s current price.

Other analysts also recently issued reports about the company. Robert W. Baird increased their target price on Haemonetics from $87.00 to $99.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. CJS Securities raised Haemonetics to a “strong-buy” rating in a report on Thursday, December 11th. JPMorgan Chase & Co. lifted their price objective on Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a report on Friday, December 12th. Citigroup lowered their target price on shares of Haemonetics from $88.00 to $75.00 and set a “neutral” rating on the stock in a research note on Friday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haemonetics in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $84.44.

Haemonetics Stock Performance

Shares of HAE stock opened at $59.35 on Friday. The company has a market capitalization of $2.78 billion, a price-to-earnings ratio of 16.35, a price-to-earnings-growth ratio of 1.23 and a beta of 0.28. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.03 and a current ratio of 1.75. Haemonetics has a one year low of $47.31 and a one year high of $87.32. The company’s 50-day moving average is $76.84 and its 200 day moving average is $65.11.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.04. The firm had revenue of $338.97 million for the quarter, compared to the consensus estimate of $331.90 million. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The business’s revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.19 earnings per share. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Sell-side analysts expect that Haemonetics will post 4.55 EPS for the current fiscal year.

Institutional Trading of Haemonetics

Several large investors have recently added to or reduced their stakes in HAE. AQR Capital Management LLC raised its position in Haemonetics by 372.8% in the third quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock worth $102,814,000 after acquiring an additional 1,678,630 shares during the period. River Road Asset Management LLC increased its stake in shares of Haemonetics by 18.7% in the 2nd quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock worth $122,586,000 after purchasing an additional 260,624 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Haemonetics by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 1,244,624 shares of the medical instruments supplier’s stock worth $92,873,000 after purchasing an additional 23,257 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Haemonetics by 2.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock worth $53,587,000 after purchasing an additional 26,763 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its position in Haemonetics by 11.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,060,790 shares of the medical instruments supplier’s stock valued at $51,777,000 after purchasing an additional 111,307 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Key Haemonetics News

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Q3 results beat consensus: HAE reported $1.31 EPS vs. $1.27 expected and revenue of $338.97M vs. ~$331.9M, with margins improving—evidence of profitable execution. Haemonetics (HAE) Q3 Earnings and Revenues Beat Estimates
• Positive Sentiment: Company raised FY‑2026 outlook and signaled strong organic growth (management highlighted plasma and blood‑management strength and an 8%–10% organic growth outlook), which supports longer‑term revenue momentum. Haemonetics raises fiscal 2026 guidance as plasma and blood management drive 8%-10% organic growth outlook
• Positive Sentiment: Analyst support remains: BTIG reaffirmed a “buy” and a $88 price target, indicating continued analyst conviction above current levels. Benzinga coverage of BTIG rating
• Neutral Sentiment: Investor materials and transparency: the company posted its press release, slide deck and earnings‑call transcript for review—useful for digging into segment trends and guidance detail. PR Newswire: Q3 financial results available
• Neutral Sentiment: Zacks highlights HAE as a top‑ranked growth stock by style scores—an informational signal for growth‑oriented investors but not an immediate price catalyst. Haemonetics (HAE) is a Top-Ranked Growth Stock: Should You Buy?
• Negative Sentiment: Revenue weakness and mixed investor reaction: revenue fell ~2.7% YoY despite the beat, and the market reacted negatively (shares slipped after the report)—suggesting investors wanted stronger top‑line improvement or more aggressive guidance. Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.